

Review

Open Access

## Progressive familial intrahepatic cholestasis

Anne Davit-Spraul<sup>1</sup>, Emmanuel Gonzales<sup>2,3</sup>, Christiane Baussan<sup>1</sup> and Emmanuel Jacquemin\*<sup>2,3</sup>

Address: <sup>1</sup>Biochemistry, Bicêtre Hospital, University of Paris-sud XI, Assistance Publique-Hôpitaux de Paris, Paris, France, <sup>2</sup>Pediatric Hepatology and National Reference Centre for Biliary Atresia, Bicêtre Hospital, University of Paris-sud XI, Assistance Publique-Hôpitaux de Paris, Paris, France and <sup>3</sup>INSERM, UMR-S757, University of Paris-sud XI, Orsay, France

Email: Anne Davit-Spraul - anne.spraul@bct.aphp.fr; Emmanuel Gonzales - emmanuel.gonzales@yale.edu; Christiane Baussan - christiane.baussan@bct.aphp.fr; Emmanuel Jacquemin\* - emmanuel.jacquemin@bct.aphp.fr

\* Corresponding author

Published: 8 January 2009

Received: 8 October 2008

*Orphanet Journal of Rare Diseases* 2009, **4**:1 doi:10.1186/1750-1172-4-1

Accepted: 8 January 2009

This article is available from: <http://www.orphandis.com/content/4/1/1>

© 2009 Davit-Spraul et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

Progressive familial intrahepatic cholestasis (PFIC) refers to heterogeneous group of autosomal recessive disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin. The exact prevalence remains unknown, but the estimated incidence varies between 1/50,000 and 1/100,000 births.

Three types of PFIC have been identified and related to mutations in hepatocellular transport system genes involved in bile formation. PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may also occur later in infancy, in childhood or even during young adulthood. Main clinical manifestations include cholestasis, pruritus and jaundice. PFIC patients usually develop fibrosis and end-stage liver disease before adulthood. Serum gamma-glutamyltransferase (GGT) activity is normal in PFIC1 and PFIC2 patients, but is elevated in PFIC3 patients. Both PFIC1 and PFIC2 are caused by impaired bile salt secretion due respectively to defects in *ATP8B1* encoding the FIC1 protein, and in *ABCB11* encoding the bile salt export pump protein (BSEP). Defects in *ABCB4*, encoding the multi-drug resistant 3 protein (MDR3), impair biliary phospholipid secretion resulting in PFIC3.

Diagnosis is based on clinical manifestations, liver ultrasonography, cholangiography and liver histology, as well as on specific tests for excluding other causes of childhood cholestasis. MDR3 and BSEP liver immunostaining, and analysis of biliary lipid composition should help to select PFIC candidates in whom genotyping could be proposed to confirm the diagnosis. Antenatal diagnosis can be proposed for affected families in which a mutation has been identified. Ursodeoxycholic acid (UDCA) therapy should be initiated in all patients to prevent liver damage. In some PFIC1 or PFIC2 patients, biliary diversion can also relieve pruritus and slow disease progression. However, most PFIC patients are ultimately candidates for liver transplantation. Monitoring of hepatocellular carcinoma, especially in PFIC2 patients, should be offered from the first year of life. Hepatocyte transplantation, gene therapy or specific targeted pharmacotherapy may represent alternative treatments in the future.

**Disease name and synonyms**

PFIC = Progressive familial intrahepatic cholestasis

PFIC1 = Progressive familial intrahepatic cholestasis type 1 = Byler disease = FIC1 deficiency

PFIC2 = Progressive familial intrahepatic cholestasis type 2 = Byler syndrome = BSEP deficiency

PFIC3 = Progressive familial intrahepatic cholestasis type 3 = MDR3 deficiency

**Definition**

Progressive familial intrahepatic cholestasis (PFIC) refers to heterogeneous group of autosomal recessive liver disorders of childhood in which cholestasis of hepatocellular origin often presents in the neonatal period or first year of life and leads to death from liver failure at ages usually ranging from infancy to adolescence [1,2]. Recent molecular and genetic studies have allowed the identification of genes responsible for three types of PFIC and have shown that they were related to mutations in hepatocellular transport system genes involved in bile formation (Figure 1).

**Epidemiology**


In our experience, PFIC represents 10 to 15% of causes of cholestasis in children and 10 to 15% of liver transplantation indications in children. PFIC1 and PFIC2 represent 2/3 of cases of PFIC, and PFIC3 1/3 of cases [3]. The true incidence of PFIC is not precisely known, but PFIC is considered a rare disease with an estimated incidence of 1/50,000 to 1/100,000 births. All types of PFIC exist worldwide. Both sexes seem to be equally affected.

**Clinical description**

Main characteristics of PFIC 1-3 are summarized in Table 1.

Cholestasis is a major clinical sign in all PFIC forms.

It usually appears in the first months of life in patients with PFIC1, and is characterized by recurrent episodes of jaundice, which become permanent later in the course of the disease. In case of PFIC2, the initial presentation and the evolution seem to be more severe, with permanent jaundice from the first months of life and rapid appearance of liver failure within the first years of life. Early hepatocellular carcinoma (before one year of age) may



**Figure 1**

**Progressive Familial Intrahepatic Cholestasis (PFIC): Types, related genes, and transport defects.** BA: bile acid; PC: phosphatidylcholine.

**Table 1: Main characteristics of Progressive Familial Intrahepatic Cholestasis (PFIC)**

	PFIC1 (Byler's disease)	PFIC2 (BSEP deficiency)	PFIC3 (MDR3 deficiency)
Transmission	autosomal recessive	autosomal recessive	autosomal recessive
Pruritus	severe	severe	moderate
Serum GGT activity	normal	normal	high
Ductular proliferation	absent	absent	present
Serum primary bile acid concentration	very high	very high	high
Bile composition	low primary bile acid concentration	very low primary bile acid concentration	low phospholipid concentration
Chromosomal locus	18q21-22	2q24	7q21
Gene/protein	<i>ATP8B1</i> FIC1	<i>ABCB11</i> BSEP	<i>ABCB4</i> MDR3
Hepatocyte location	canalicular membrane	canalicular membrane	canalicular membrane
Other sites of expression	Cholangiocytes Intestine, Pancreas	none	none
Functional defect	ATP-dependent aminophospholipid transport	ATP-dependent bile acid transport in bile	ATP-dependent phosphatidylcholine translocation in bile

complicate the course of PFIC2. Severe pruritus is usually observed in PFIC1 and PFIC2 patients. Phenotypic findings in PFIC1 and PFIC2 are similar, but some slight phenotypic difference have been identified [1,4-8]. Extrahepatic features that have been reported in PFIC1 patients (persistent short stature, sensorineural deafness, watery diarrhea, pancreatitis, elevated sweat electrolyte concentration, liver steatosis) [9], have not been described in PFIC2. In PFIC3, clinical signs of cholestasis are noted within the first year of life in about one third of patients and rarely in the neonatal period, in contrast to PFIC1 and 2. PFIC3 may also manifest later in infancy, in childhood or even in young adulthood. Gastrointestinal bleeding due to portal hypertension and cirrhosis is the presenting symptom in adolescent or young adult patients. Pruritus is usually mild. Evolution is characterized by chronic icteric or anicteric cholestasis, portal hypertension and liver failure. In half of the patient, liver transplantation is required at a mean age of 7.5 years. No liver tumor has yet been reported in association with PFIC3 [10].

### Laboratory findings


Patients with PFIC1 and PFIC2 have normal serum gamma-glutamyltransferase (GGT) activity, normal

serum cholesterol level and very high serum bile acid concentration. Although PFIC1 and PFIC2 share similar laboratory findings, PFIC2 patients have higher transaminase and alpha-fetoprotein serum levels at diagnosis than those with PFIC1 [1,4-9]. Patients with PFIC3 have a persistent high serum GGT activity, normal serum cholesterol level and moderately raised concentrations of serum primary bile salts.

### Histological findings

In PFIC1 patients, liver histology is characterized by canalicular cholestasis and the absence of true ductular proliferation with only periportal biliary metaplasia of hepatocytes. In PFIC2 patients, the same signs are seen but the liver architecture is more perturbed, with more pronounced lobular and portal fibrosis and inflammation. Hepatocellular necrosis and giant cell transformation is also much more pronounced in PFIC2 than in PFIC1 and may persist with time. These differences between PFIC1 and PFIC2 likely reflect the severe lobular injury present in PFIC2 (Figure 2A-B) [1,8,9].

In PFIC3, liver histology, obtained at the time of diagnosis (Figure 2C), shows portal fibrosis and true ductular prolif-

**Figure 2**

**Liver histology.** A: liver histology in a PFIC1 patient at age six months. It shows moderate lobular and portal fibrosis; B: liver histology in a PFIC2 patient at age 11 months. It shows hepatocellular necrosis, giant cell transformation and cirrhosis; C: liver histology in a PFIC3 patient at age 10 months. It shows strong (true) ductular proliferation within the all portal tract; D: at age 5 years in the same PFIC3 patient, there is a typical picture of biliary cirrhosis with ductules containing bile plugs, while patent biliary tree.

eration with mixed inflammatory infiltrate. In a few instances, cholestasis is present in the lobule and in some ductules containing bile plugs. Slight giant transformation of hepatocytes can be observed. Cytokeratin immunostaining confirms the strong ductular proliferation within the portal tract. At a later stage (Figure 2D), there is extensive portal fibrosis and a typical picture of biliary cirrhosis. Interlobular bile ducts are seen in most portal tracts and there is neither periductal fibrosis nor biliary epithelium injury [11].

## Etiology

### PFIC 1

The first type, called PFIC1 (Byler disease) is caused by mutations in the *ATP8B1* gene (also designated FIC1) [6,12]. This gene, which encodes a P-type ATPase, is located on human chromosome 18 and is also mutated in the milder phenotype, benign recurrent intrahepatic cholestasis type 1 (BRIC1) and in Greenland familial cholestasis [6,12,13]. FIC1 protein is located on the canalicular membrane of the hepatocyte but within the liver it is mainly expressed in cholangiocytes [14-16]. The function of this P-type ATPase is unknown but it could be an aminophospholipid transporter responsible for maintaining the enrichment of phosphatidylserine and phosphatidylethanolamine on the inner leaflet of the plasma membrane in comparison of the outer leaflet [6,14]. The asymmetric distribution of lipids in the membrane bilayer plays a protective role against high bile salt concentrations in the canalicular lumen [17]. How mutations in this protein cause cholestasis is unclear. It is postulated that abnormal protein function might indirectly disturb the biliary secretion of bile acids, explaining the low biliary bile acid concentration found in PFIC1 patients [4,6]. Different studies have shown that impaired *ATP8B1* function in patients with PFIC1 results in substantial downregulation of FXR, a nuclear receptor involved in the regulation of bile acid metabolism with subsequent downregulation of BSEP in the liver and upregulation of bile acid synthesis, and of the apical sodium bile salt transporter (ASBT) in the intestine [16,18,19]. All in all, these events lead to hepatocyte bile acid overload. Moreover, evidence for cystic fibrosis transmembrane conductance regulator (CFTR) down regulation in cholangiocytes has also been reported in patients with PFIC1 which could contribute to impairment of bile secretion and explain some extrahepatic features [16].

The *ATP8B1* gene is expressed in various organs, including the liver, pancreas, kidney and small intestine, but is more highly expressed in the small intestine than in the liver [12]. Therefore, it is thought to also be involved in the enterohepatic cycling of bile salts. This may also explain the chronic diarrhea present in a few children with PFIC1. Other extrahepatic features associated with PFIC1 such as

persistent short stature, deafness and pancreatitis suggest a general cell biological function for FIC1 [6,9,20].

It is very likely that FIC1 disease represents a continuum with intermediate phenotypes between the benign phenotype BRIC1 and the severe phenotype PFIC1 [6]. So far, there is no clear explanation for the phenotypic difference between patients with BRIC1 and those with PFIC1. Mutation analyses suggest that mutations identified in patients with PFIC1 would severely disrupt protein function, whereas protein function would be only partially impaired in patients with BRIC1 [21]. Genotype-phenotype associations will probably be complicated because dramatic variability in phenotypic presentation has already been identified in patients with BRIC1 with a common mutation. In addition, many patients with FIC1 disease are compound heterozygous, which will also complicate the identification of genotype-phenotype correlations [21]. Heterozygous *ATP8B1* mutations have also been identified in some cases of intrahepatic cholestasis of pregnancy (ICP), that can be referred to under the term ICP type 1 (ICP1) [22,23].

### PFIC 2

The second type, called PFIC2, is caused by mutations in the *ABCB11* gene (also designated *BSEP*) [7,24]. Initially, PFIC2 was reported under the name Byler syndrome [1,4]. The *ABCB11* gene encodes the ATP-dependent canalicular bile salt export pump (BSEP) of human liver and is located on human chromosome 2. BSEP protein, expressed at the hepatocyte canalicular membrane, is the major exporter of primary bile acids against extreme concentration gradients. Mutations in this protein are responsible for the decreased biliary bile salt secretion described in affected patients, leading to decreased bile flow and accumulation of bile salts inside the hepatocyte with ongoing severe hepatocellular damage.

BSEP deficiency represents also a phenotypic continuum between BRIC2 and PFIC2. So far, no clear genotype-phenotype correlation has been identified among PFIC2 patients, but most children with BSEP mutations, regardless of the mutation type, had no canalicular BSEP protein expression [5]. Severe phenotypes are often associated with mutations leading to premature protein truncation or failure of protein production. Insertion, deletion, non sense and splicing mutations result in damaging effects and patients exhibited little or no detectable BSEP at the hepatocyte canaliculus. Missense mutations are also common defects [25] that either affect protein processing and trafficking (*i.e.* p.E297G, p.D482G) [26,27] or disrupt functional domains and protein structure. Thus detectable BSEP expression (*i.e.* p.N490D, p.G562D, p.R832C, p.A1110E) does not exclude functional BSEP deficiency.

Some mutations have been functionally characterized confirming the defect of bile acid secretion [28,29].

In milder disease, such as BRIC2 [30], missense mutations predominate over those leading to failure of protein production and mutations occur in less conserved regions than in the NBFs (nucleotide binding fold) which contain the Walker A/B motifs and ABC signature. Cholelithiasis was also reported in BRIC2 patients [[30,31] and E. Jacquemin personal data]. Heterozygous *ABCB11* mutations have also been identified in cases of ICP (ICP2) [32], drug induced cholestasis [33] and transient neonatal cholestasis [34].

### PFIC 3

The third type of PFIC, called PFIC3, is caused by a genetic defect in the *ABCB4* gene (also designated *MDR3*) located on chromosome 7. Class III Multidrug Resistance (*MDR3*) P-glycoprotein (P-gp), is a phospholipid translocator involved in biliary phospholipid (phosphatidylcholine) excretion and is predominantly, if not exclusively, expressed in the canalicular membrane of the hepatocyte [10]. Cholestasis results from the toxicity of bile in which detergent bile salts are not inactivated by phospholipids, leading to bile canaliculi and biliary epithelium injuries. The mechanism of liver damage in PFIC3 patients is likely related to the absence of biliary phospholipids [11]. Injury to bile canaliculi and biliary epithelium results probably from continuous exposure to hydrophobic bile salts, the detergent effects of which are no longer countered by phospholipids, leading to cholangitis [11]. In addition, the stability of mixed micelles in bile is determined by a three-phase system, in which a proper proportion of bile salts and phospholipids are necessary to maintain solubility of cholesterol. The absence of phospholipids in bile would be expected to destabilize micelles and promote lithogenicity of bile with crystallization of cholesterol, which could favor small bile duct obstruction. These cholangiopathy mechanisms fit well with the histologic findings such as ductular proliferation. PFIC3 represents an important example of canalicular transport defect that leads to the development of cholangiopathy.

The phenotypic spectrum of PFIC3 ranges from neonatal cholestasis to cirrhosis in young adults [11,35]. In our experience, *ABCB4* sequence analysis in 50 PFIC3 patients revealed around 30 different *ABCB4* mutations. Mutations were characterized on both alleles in most cases. In one third of cases, mutations gave rise to a truncated protein. When tested, no *MDR3* P-glycoprotein could be detected by immunostaining in the liver of these patients. The absence of *MDR3* protein can be explained in two ways. The truncated protein may be broken down very rapidly after synthesis giving rise to extremely low steady

state levels of the protein. More likely, the premature stop codon may lead to instability and decay of the *ABCB4* mRNA. This latter explanation is supported by the near absence of *ABCB4* mRNA in northern blottings on liver samples from several patients [36,37]. The remaining 2/3 of patients had missense mutations. Some of them were found in the highly conserved aminoacid sequences of the Walker A and B motifs which are involved in ATP-binding [38]. Such aminoacid changes in the Walker A or B motif are generally not compatible with ATPase activity and transport processes [38-41]. Alternatively, missense mutations might result in intracellular misprocessing of *MDR3* as shown for other ABC transporters [27,42-44]. Indeed, such missense mutations were associated with a decreased level of *MDR3* canalicular protein [44]. Whatever the mechanism involved, the low level of biliary phospholipids found in patients with missense mutations demonstrates the *MDR3* functional defect [11]. There is now strong evidence that in addition to PFIC3, an *MDR3* defect can be involved in ICP (ICP3) [32,43,45-48], cholesterol gallstone disease [49-52] and drug induced cholestasis [53-55]. A *MDR3* defect is also likely to be involved in some cases of transient neonatal cholestasis and adult idiopathic cirrhosis [10,35,56]. *MDR3* deficiency may also represent a clinical continuum, as a single patient may experience different phenotypes during the disease course, starting with cholesterol cholelithiasis, then ICP and ending with biliary cirrhosis [57].


### Diagnosis and diagnostic methods

PFIC should be suspected in children with a clinical history of cholestasis of unknown origin after exclusion of other main causes of cholestasis, (e.g. biliary atresia, Alagille syndrome, alpha1antitrypsin deficiency, cystic fibrosis, sclerosing cholangitis and extrahepatic bile duct obstruction) [11]. High serum bile acid concentration excludes primary disorders of bile acid synthesis [58]. Patients with PFIC1 and PFIC2 have normal serum GGT activity, while patients with PFIC3 have high serum GGT activity. PFIC3 patients can also be distinguished from patients with the other types of PFIC (PFIC1 and PFIC2) in that they present rarely with cholestatic jaundice at the neonatal period, but rather later in infancy, in childhood or in young adulthood. A schematic approach to the diagnosis of PFIC is proposed in Figure 3. This combined clinical, biochemical, radiological and histological approach associated with liver immunostaining and biliary lipid analysis, should help to select PFIC candidates in whom a molecular diagnosis can be proposed.

### Diagnostic methods

#### • Radiological approach

Initial ultrasonography of the liver is performed to exclude biliary tract disease. Typically, ultrasonography is normal but may reveal a huge gallbladder. Sometimes,



**Figure 3**  
Schematic approach to the diagnosis of PFIC excluding the neonatal period, during which biliary atresia is the main cause of cholestasis.

biliary stones may be identified. When performed, cholangiography shows a normal biliary tree, excluding sclerosing cholangitis, and allows bile to be collected for biliary lipid analysis [11].

#### • Liver histology

is important for diagnosis. It also allows liver immunostaining to be performed. Typical features were described in the clinical description section and are shown in Figure 2. When signs of biliary obstruction are seen at liver biopsy, as may occur in PFIC3, cholangiography must be performed to exclude sclerosing cholangitis [11,59].

#### • Liver immunostaining

Commercially available MDR3 and BSEP antibodies allow liver immunostaining to be performed [5,11,25]. Absence of canalicular or mild immunostaining are in favor of a gene defect. Normal staining does not exclude a gene defect as a mutation may induce a loss of function but normal synthesis and addressing.

#### • Electron microscopy

Typical ultrastructural aspects of bile may allow differentiation of PFIC1 and PFIC2 but liver ultrastructural histology is not easily available [4,60].

#### • Biliary lipid analysis

Biliary lipid analysis is performed on gallbladder bile or on bile collected by duodenal aspiration (pure choledochal bile). In case of gallbladder puncture, bile contamination by blood may falsify bile analysis. In case of duodenal aspiration, bile dilution or bile contamination by alimentary phospholipids may falsify bile analysis. The biliary bile salt concentration is dramatically decreased (<1 mM) in PFIC2 patients [5] and only mildly decreased in PFIC1 patients (3–8 mM) [9] and A. Davit-Spraul, personal data]. The normal concentration of biliary primary bile salts distinguishes PFIC3 patients from those with PFIC1 and PFIC2 [4,5,11,58]. In PFIC3 patients, the biliary phospholipid level is dramatically decreased (1–15% of total biliary lipids; normal range 19–24%). Biliary bile salt:phospholipid and cholesterol:phospholipid ratios are approximately 5-fold higher than in wild type bile. The residual percentage of biliary phospholipids seems

directly related to the severity of *MDR3* mutation and consequently to the residual activity of the *MDR3* P-glycoprotein. Patients with "severe" mutations (nonsense, frameshift) have a low percentage of biliary phospholipids <2%, while patients with missense mutations have a high percentage of biliary phospholipids  $\geq$  2%. In our experience, the threshold that predicts a positive response to ursodeoxycholic acid (UDCA) therapy in PFIC3, is represented by a percentage of biliary phospholipids of around 7%. The combination of abnormal *MDR3* canalicular immunostaining and low percentage of biliary phospholipids is highly suggestive of *MDR3* deficiency.

#### • Molecular analysis

PFIC1: *ATP8B1* gene (coding exons 2–28)

PFIC2: *ABCB11* gene (coding exons 2–28)

PFIC3: *ABCB4* gene (coding exons 2–28)

Gene analysis is usually performed by DNA sequencing of the 27 coding exons and their splice junctions. In case of silent or intronic mutations, a *in silico* test is helpful to predict a potential splice defect which must be confirmed by RNA analysis (RT-PCR and sequencing) [61]. The use of a resequencing chip dedicated to genetic cholestasis could facilitate identification of gene mutation [62].

#### • <sup>31</sup>P MRS spectroscopy

It remains to be evaluated if <sup>31</sup>P MRS (Magnetic Resonance Spectroscopy) would be a valuable non-invasive tool to characterize canalicular transport defects, such as was suggested for ICP1 [22].

#### Differential diagnosis

Several other autosomal recessive PFIC-like diseases are known. Liver diseases resembling PFIC with normal GGT activity have been identified as inborn errors in primary bile acid synthesis and represent distinct disorders [58]. Other liver diseases resembling PFIC with normal serum GGT activity are recognized. Familial Amish hypercholanemia represents a PFIC-like disorder not due to a primary defect of the transport system involved in bile formation, but to a tight junction protein defect combined with a defect of primary bile acid conjugation [63,64]. Cholestasis is due to impaired transport of unconjugated bile acids into bile and to bile leakage into plasma through abnormal canalicular tight junctions increasing paracellular permeability. Another category of progressive cholestatic liver disease of childhood could be due to abnormal villin expression, leading to loss of structural integrity of canalicular microvilli impairing biliary secretion system function [65]. A case of hypercholanemia due to mutations in the m-epoxide hydrolase gene has also been reported (*EPHX1*) [66,67]. Arthrogyrosis-renal dys-

function cholestasis syndrome is a complex disease due to mutation of *VPS33B* involved in intracellular trafficking and targeting of apical proteins. The gene defect results in a loss of apical protein expression in the liver and kidneys [68]. From a liver point of view, it represents another PFIC-like disorder with normal GGT activity. In cases of high serum GGT activity, sclerosing cholangitis must be excluded [59,69]. North American Indian Childhood Cirrhosis due to a defect in the *cirrhin* gene is characterized by high GGT activity [70] as is Agenes syndrome, a lymphedema cholestasis syndrome of unknown cause [71].

#### Genetic counseling and antenatal diagnosis

Genotyping should be used to confirm the diagnosis of PFIC in affected children. Heterozygosity of parents for the defects found in affected patients confirmed the recessive inheritance of the disease. This understanding has already allowed prenatal diagnosis. Antenatal diagnosis of PFIC requires clinical and biochemical expertise [56].

#### Specific management including treatment

Therapy with UDCA should be considered in the initial therapeutic management of children with all types of PFIC [72]. UDCA therapy may be effective in some patients, especially those with PFIC3 with missense mutations who have less severe disease in comparison to children with a mutation leading to a truncated protein [11].

Some patients with PFIC1 or PFIC2 may also benefit from surgical biliary diversion [73,74]. Nasobiliary drainage may help to select potential responders to biliary diversion [75]. So far, clear genotype-phenotype correlation data are missing and remain to be defined in order to identify those PFIC1-2 patients who could benefit from UDCA or biliary diversion [3,60]. Preliminary data suggest that PFIC2 patients with p.D482G or p.E297G mutations may respond well to biliary diversion [60].

If these therapies fail, liver transplantation represents the only alternative [76]. In our experience, extrahepatic features, such as diarrhea, liver steatosis and short stature sometimes associated with PFIC1, do not improve or may be aggravated after successful biliary diversion or liver transplantation [9]. Chronic diarrhea may become intractable when biliary bile salt secretion is restored after liver transplantation [6,9,20]. It is often associated with severe liver steatosis and/or steatohepatitis that may lead to cirrhosis with time and to indication to retransplantation. Liver steatosis and diarrhea may recur after retransplantation (E. Jacquemin, personal data). Diarrhea might be favorably managed by bile adsorptive resin treatment [9,20].



In the future, therapies such as cell, gene or specific targeted pharmacological therapies (*i.e.* FXR inducers, chaperone drugs), might represent an alternative therapy for all types of PFIC [27,60,77-79]. In PFIC2, it is uncertain whether hepatocyte transplantation or gene therapy with modified hepatocytes represents a good therapeutic approach. Indeed, with this approach, it may be a risk to leave premalignant liver cells in place, especially in patients with severe biallelic *ABCB11* mutations [80].

### Prognosis

In addition to the natural history and complications of PFIC1-3 (portal hypertension, liver failure, cirrhosis, hepatocellular carcinoma, extrahepatic manifestations), children with PFIC1-3 are theoretically at risk of developing further in the disease course, biliary stones, drug-induced cholestasis and ICP. Girls under UDCA therapy who reach adulthood with their native liver must not stop UDCA during pregnancy because of the risk of developing severe ICP as seen in a previously reported patient [53] who became pregnant (personal data Dr N. Ganne-Carrié, Hepatology Unit, Jean Verdier Hospital, Bondy, France).

Patients with BSEP deficiency, especially those with biallelic truncating mutations, are at considerable risk for hepatobiliary malignancy (15% may develop hepatocellular carcinoma or cholangiocarcinoma) [[25,80] and E. Jacquemin personal data]. These findings justify close monitoring of hepatocellular carcinoma (At least, serum alpha fetoprotein dosage every 6 months and liver ultrasonography every year) in PFIC2 patients from the first year of life.

### Unresolved questions

In very rare PFIC patients (< 10%), only one mutated allele or no mutation is identified. This can be explained by mutations that may map to regulatory sequences of the genes. A gene involved in the transcription of PFIC genes (*i.e.* FXR) or in protein trafficking could also be involved [81,82]. It is also possible that other unidentified genes involved in bile formation may be responsible for the PFIC1-3 phenotypes. Furthermore, it may be hypothesized that combined heterozygous mutations for two genes (*i.e.* *MDR3* and *BSEP*) lead to PFIC like phenotype [49]. An interesting possibility is also that in a heterozygous state, the mutated protein may have a dominant negative effect on protein expression/function [83]. Modifier genes and environmental influences could play a role in the expression of PFIC [58].

After liver transplantation the possible "recurrence of PFIC" on liver grafts due to alloimmunization of the recipient against the BSEP, MDR3 or FIC1 proteins of liver donor remains a theoretical matter of debate. It is hypothesized that PFIC patients with a severe mutation leading

to absence of the gene product would be immunologically naive for the FIC1, BSEP or MDR3 gene products. In this context, alloimmunization could occur after liver transplantation. To our knowledge, this complication has not been reported so far after liver transplantation [76,84] but we have observed a case of an PFIC2 male patient who experienced an unexplained severe bout of pure hepatocellular cholestasis resembling PFIC2 after cadaveric liver transplantation (E. Jacquemin, personal data). In addition, in case of parental living donor transplantation, it could be expected that the heterozygous status of the liver graft leads to a predisposition for developing lithiasis or cholestasis favored by immunosuppressive drugs [33] that may interfere with canalicular protein function, as we have seen in a PFIC2 patient (E. Jacquemin, personal data). Nevertheless, this complication is likely to be very rare, since it has not been reported in a broad series of living donor transplantation for PFIC [84].

### Experimental perspectives

As already mentioned above, studies performed in cell lines have determined the effects of some PFIC gene mutations (*ATP8B1* [17-19], *ABCB11* [26,28,29], *ABCB4* [41,43,44]). This should allow testing of some drugs that may restore, at least partially, the function or the targeting of a mutated protein [27,78,79]. Besides these cell studies, mouse models of PFIC1-3 have been created by genetic engineering [85-87]. Mainly, the PFIC1-2 models have demonstrated that the phenotypes of the mice were much less severe than in humans. Although the phenotypes were aggravated by supplementation with cholic acid, the main bile salt in humans, this was not sufficient to induce liver injury comparable to that seen in PFIC1-2 patients. The likely reason for this is that mice, unlike humans, may easily detoxify hydrophobic bile salts by hydroxylation, *via* the cytochrome P450 enzyme system, resulting in a less cytotoxic bile salt pool. Therefore, it would be interesting to generate new mouse models that closely resemble PFIC1-2. Recently, cytochrome P450 knockout mice have been generated [88]. It is expected that crossing PFIC mouse models with mice with a disrupted liver cytochrome P450 oxidoreductase gene will generate mice sensitive to human bile salts. Such new mouse models could develop liver diseases that closely reproduce PFICs and will allow better experimental studies of the pathophysiology of PFICs and test the effects of treatments.

### List of abbreviations

PFIC: Progressive familial intrahepatic cholestasis; GGT: gamma-glutamyltransferase; BSEP: bile salt export pump protein; UDCA: Ursodeoxycholic acid; ICP: intrahepatic cholestasis of pregnancy; BRIC: benign recurrent intrahepatic cholestasis; ASBT: apical sodium bile salt transporter; CFTR: cystic fibrosis transmembrane conductance regulator; NBFs: nucleotide binding folds; MDR3: Class III

Multidrug Resistance; P-gp: P-glycoprotein; MRS: Magnetic Resonance Spectroscopy; FXR: farnesoid X receptor.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

The authors equally contributed to this review article. They read and approved the final version of the manuscript.

### References

- Jacquemin E: **Progressive familial intrahepatic cholestasis: genetic basis and treatment.** In: *Pediatric liver.* *Clin Liver Dis* 2000, **4**:753-763.
- Van Mil SWC, Houwen RHJ, Klomp LWJ: **Genetics of intrafamilial cholestasis syndromes.** *J Med Genet* 2005, **42**:449-463.
- Baussan C, Cresteil D, Gonzales E, Raynaud N, Dumont M, Bernard O, Hadchouel M, Jacquemin E: **Genetic cholestatic liver diseases: The example of progressive familial intrahepatic cholestasis and related disorders.** *Acta Gastroenterol Belg* 2004, **64**(3):179-183.
- Bull LN, Carlton VEH, Stricker NL, Baharloo S, DeYoung JA, Freimer NB, Magid MS, Kahn E, Markowitz J, DiCarlo FJ, McLoughlin L, Boyle JT, Dahms BB, Faught PR, Fitzgerald JF, Piccoli DA, Witzleben CL, O'Connell NC, Setchell KD, Agostini RM Jr, Kocoshis SA, Reyes J, Knisely AS: **Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): Evidence for heterogeneity.** *Hepatology* 1997, **26**:155-164.
- Jansen PLM, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJE, Koning JH, de Jager-Krieken A, Kuipers F, Stellard F, Bijleveld CMA, Gouw A, van Goor H, Thompson RJ, Muller M: **Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis.** *Gastroenterology* 1999, **117**:1370-1379.
- Van Mil SWC, Klomp L, Bull LN, Houwen RH: **FIC1 disease: A spectrum of intrahepatic cholestatic disorders.** *Semin Liv Dis* 2001, **21**:535-544.
- Thompson R, Strautnieks S: **BSEP: function and role in progressive familial intrahepatic cholestasis.** *Semin Liv Dis* 2001, **21**:545-550.
- Chen HL, Chang PS, Hsu HC, Ni YH, Hsu HY, Lee JH, Jeng YM, Shau WY, Chang MH: **FIC1 and BSEP defects in taiwanese patients with chronic intrahepatic cholestasis with low gamma-glutamyltranspeptidase levels.** *J Pediatr* 2002, **140**:119-124.
- Lykavieris P, van Mil S, Cresteil D, Fabre M, Hadchouel M, Klomp L, Bernard O, Jacquemin E: **Progressive familial intrahepatic cholestasis type I and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation.** *J Hepatol* 2003, **39**:447-452.
- Jacquemin E: **Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases.** *Semin Liv Dis* 2001, **21**:551-562.
- Jacquemin E, de Vree JLM, Cresteil D, Sokal EM, Sturm E, Dumont M, Scheffer GL, Paul M, Burdelski M, Bosma PJ, Bernard O, Hadchouel M, Oude Elferink RPJ: **The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.** *Gastroenterology* 2001, **120**:1448-1458.
- Bull LN, van Eijk MJT, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, Klomp LWJ, Lomri N, Berger R, Scharnschmidt BR, Knisely AS, Houwen RHJ, Freimer NB: **A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis.** *Nat Genet* 1998, **18**:219-224.
- Klomp LWJ, Bull LN, Knisely AS, Doelen MA van Der, Juijn JA, Berger R, Forget S, Nielsen IM, Eiberg H, Houwen RH: **A missense mutation in FIC1 is associated with greenland familial cholestasis.** *Hepatology* 2000, **32**:1337-1341.
- Ujhazy P, Ortiz D, Misra S, Li S, Moseley J, Jones H, Arias IM: **Familial intrahepatic cholestasis I: studies of localization and function.** *Hepatology* 2001, **34**:768-775.
- Eppens EF, van Mil SW, de Vree JM, Mok KS, Juijn JA, Oude Elferink RP, Berger R, Houwen RH, Klomp LW: **FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte.** *J Hepatology* 2001, **35**:436-443.
- Demeilliers C, Jacquemin E, Barbu V, Mergey M, Paye F, Fouassier L, Chignard N, Housset C, Lomri NE: **Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation.** *Hepatology* 2006, **43**:1125-1134.
- Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, Rudi de Waart D, Hoek FJ, Vreeling H, Hoeben KA, van Marle J, Pawlikowska L, Bull LN, Hofmann AF, Knisely AS, Oude Elferink RP: **Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport.** *Hepatology* 2006, **44**:195-204.
- Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull LN, Knisely AS, Strautnieks SS, Thompson RJ, Magid MS, Gordon R, Balasubramanian N, Suchy FJ, Shneider BL: **Progressive familial intrahepatic cholestasis, type I, is associated with decreased farnesoid X receptor activity.** *Gastroenterology* 2004, **126**:756-764.
- Alvarez L, Jara P, Sánchez-Sabaté E, Hierro L, Larrauri J, Díaz MC, Camarena C, De la Vega A, Frauca E, López-Collazo E, Lapunzina P: **Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1.** *Hum Mol Genet* 2004, **13**:2451-2460.
- Egawa H, Yorifuji T, Sumazaki R, Kimura A, Hasegawa M, Tanaka K: **Intractable diarrhea after liver transplantation for Byler's disease: successful treatment with bile adsorptive resin.** *Liver Transplant* 2002, **8**:714-716.
- Klomp LWJ, Vargas JC, Van Mil SWC, Pawlikowska L, Strautnieks SS, Van Eijk MJT, Juijn JA, Pabón-Peña C, Smith LB, DeYoung JA, Byrne JA, Gombert J, Brugge G Van Der, Berger R, Jankowska J, Villa E, Knisely AS, Thompson RJ, Freimer NB, Houwen RHJ, Bull LN: **Characterization of mutations in ATP8B1 Associated with hereditary cholestasis.** *Hepatology* 2004, **40**:27-38.
- Müllenbach R, Bennett A, Tetlow N, Patel N, Hamilton G, Cheng F, Chambers J, Howard R, Taylor-Robinson SD, Williamson C: **ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy.** *Gut* 2005, **54**:829-834.
- Painter JN, Savander M, Ropponen A, Nuponen N, Riikonen S, Ylikorkala, Lehesjoki AE, Aittomäki K: **Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy.** *Eur J Hum Genet* 2005, **13**:435-439.
- Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Németh A, Pawlowska J, Baker A, Mieli-Vergani G, Freimer NB, Gardiner RM, Thompson RJ: **A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis.** *Nat Genet* 1998, **20**:233-238.
- Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerová D, Rayner A, Dutton L, Meier Y, Antoniou A, Stieger B, Arnell H, Özçay F, Al-Hussaini HF, Bassas AF, Verkade HJ, Fischler B, Németh A, Kotalová R, Shneider BL, Cielecka-Kuszyk J, McClean P, Whittington PF, Sokal E, Jirsa M, Wali SH, Jankowska I, Pawlowska J, Mieli-Vergani G, Knisely AS, Bull LN, Thompson RJ: **Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families.** *Gastroenterology* 2008, **134**:1203-1214.
- Hayashi H, Takada T, Suzuki H, Akita H, Sugiyama Y: **Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11.** *Hepatology* 2005, **41**:916-924.
- Hayashi H, Sugiyama Y: **4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps.** *Hepatology* 2007, **45**:1506-1516.
- Lam P, Pearson CL, Soroka CJ, Xu S, Mennone A, Boyer JL: **Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases.** *Am J Physiol Cell Physiol* 2007, **293**:C1709-16.
- Kagawa T, Watanabe N, Mochizuki K, Numari A, Ikono Y, Itoh J, Tanaka H, Arias IM, Mine T: **Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells.** *Am J Physiol Gastrointest Liver Physiol* 2008, **294**:G58-67.

30. Van Mil SWC, Woerd WL Van den, Brugge G Van den, Sturm E, Jansen PLM, Bull LN, Berg IET Van den, Berger R, Houwen RHJ, Klomp LWJ: **Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11.** *Gastroenterology* 2004, **127**:379-384.
31. Kong FM, Sui CY, Li YJ, Guo KJ, Guo RX: **Hepatobiliary membrane transporters involving in the formation of cholesterol calculus.** *Hepatobiliary Pancreat Dis Int* 2006, **5**:286-289.
32. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breyman C, Zimmermann R, Kenngott S, Beuers U, Reichel C, Kerb R, Penger A, Meier PJ, Kullak-Ulbick GA: **Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.** *Pharmacogenetics* 2004, **14**:91-102.
33. Pauli-Magnus C, Meier PJ: **Hepatobiliary transporters and drug-induced cholestasis.** *Hepatology* 2006, **44**:778-787.
34. Hermeziu B, Sanlaville D, Girard M, Léonard C, Lyonnet S, Jacquemin E: **Heterozygous bile salt export pump deficiency: a possible genetic predisposition to transient neonatal cholestasis.** *J Pediatr Gastroenterol Nutr* 2006, **42**:7-8.
35. Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrié N: **ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults.** *Gastroenterology* 2008, **135**:131-141.
36. Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, Bernard O, Hadchouel M: **Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis.** *Hepatology* 1996, **23**:904-908.
37. De Vree JML, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, Desrochers M, Burdelski M, Bernard O, Oude Elferink RPJ, Hadchouel M: **Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.** *Proc Natl Acad Sci USA* 1998, **95**:282-287.
38. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I: **Genetic analysis of the multidrug transporter.** *Annu Rev Genet* 1995, **29**:607-649.
39. Beaudet L, Urbatsch IL, Gros P: **Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity.** *Biochemistry* 1998, **37**:9073-9082.
40. Urbatsch IL, Beaudet L, Carrier I, Gros P: **Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites.** *Biochemistry* 1998, **37**:4592-4602.
41. Morita SY, Kobayashi A, Takanezawa Y, Kioka N, Handa T, Arai H, Matsuo M, Ueda K: **Bile salt-dependant efflux of cellular phospholipids mediated by ATP binding cassette protein B4.** *Hepatology* 2007, **46**:188-199.
42. Riordan JR: **Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.** *Am J Hum Genet* 1999, **64**:1499-1504.
43. Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, Weaver J, Nielson-Piercy C, De Sweit M, Warnes G, Elias E, Higgins CF, Johnston DG, McCarty MI, Williamson C: **Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking.** *Hum Mol Genet* 2000, **9**:1209-1217.
44. Durand-Schneider AM, Abarane A, Delautier D, Ait Slimane T, Delaunay JL, Gora S, Trugnan G, Jacquemin E, Maurice M: **Effect of missense mutations of the MDR3 gene identified in patients with progressive familial intrahepatic cholestasis type III.** *Hepatology* 2003, **44**:622A.
45. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M: **Heterozygous non-sense mutation of MDR3 gene in familial intrahepatic cholestasis of pregnancy.** *Lancet* 1999, **353**:210-211.
46. Müllenbach R, Linton KJ, Wiltshire S, Weerasekera N, Chambers J, Elias E, Higgins CF, Johnston DG, McCarty MI, Williamson C: **ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy.** *J Med Genet* 2003, **40**:e70-74.
47. Gendrot C, Bacq Y, Brechot MC, Lansac J, Andres C: **A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy.** *J Med Genet* 2003, **40**:e32-34.
48. Keitel V, Vogt C, Haussinger D, Kubitz R: **Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy.** *Gastroenterology* 2006, **131**:624-629.
49. Rosmorduc O, Hermelin B, Poupon R: **MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis.** *Gastroenterology* 2001, **120**:1459-1467.
50. Rosmorduc O, Hermelin B, Boelle PY, Parc R, Taboury J, Poupon R: **ABCB4 gene mutation-associated cholelithiasis in adults.** *Gastroenterology* 2003, **125**:452-459.
51. Kano M, Shoda J, Sumazaki R, Oda K, Nimur Y, Tanaka N: **Mutations identified in human multidrug resistance P-glycoprotein 3 (ABCB4) gene in patients with primary hepatolithiasis.** *Hepatal Res* 2004, **29**:160-166.
52. Rosmorduc O, Poupon R: **Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene.** *Orphanet J Rare Dis* 2007, **2**:29-34.
53. Ganne-Carrié N, Baussan C, Grando V, Gaudelus J, Cresteil D, Jacquemin E: **Progressive familial intrahepatic cholestasis type 3 revealed by oral contraceptive pills.** *J Hepatal* 2003, **38**:693-694.
54. Trauner M, Fickert P, Wagner M: **MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes.** *Semin Liver Dis* 2007, **27**:77-98.
55. Lang C, Meier Y, Stieger B, Ulrich B, Lang T, Kerb R, Kullak-Ulbick GA, Meier PJ, Pauli-Magnus C: **Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury.** *Pharmacogenet Genomics* 2007, **17**:47-60.
56. Jung C, Driancourt C, Baussan C, Zater M, Hadchouel M, Meunier-Rotival M, Guiochon-Mantel A, Jacquemin E: **Prenatal molecular diagnosis of inherited cholestatic diseases.** *J Pediatr Gastroenterol Nutr* 2007, **44**:453-458.
57. Lucena JF, Herrero JL, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, Sola J, Herraiz M, Medina JF, Prieto J: **A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis.** *Gastroenterology* 2003, **124**:1037-1042.
58. Balistreri WF: **Inborn errors of bile acid biosynthesis and transport: Novel form of metabolic liver diseases.** *Gastroenterol Clin North Am* 1999, **28**:145-172.
59. Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O: **Sclerosing cholangitis in children.** *J Pediatr* 1994, **124**:49-56.
60. Balistreri WF, Bezzera JA, Jansen P, Karpen SJ, Shneider BJ, Suchy FK: **Intrahepatic cholestasis: summary of an American association for study of liver diseases single-topic conference.** *Hepatology* 2005, **42**:222-235.
61. Houdayer C, Dehainault C, Mattler C, Michaux D, Caux-Moncoutier V, Pages-Berhouet S, Dubois d'Enghein, Laugé A, Castera L, Gauthier-Villars M, Stoppa-Lyonnet D: **Evaluation of in silico tools for decision making in molecular diagnosis.** *Human Mut* 2008, **29**:975-982.
62. Liu C, Aronow BJ, Jegga AG, Wang N, Miethke A, Mourya R: **Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis.** *Gastroenterology* 2007, **132**:119-126.
63. Morton DH, Salen G, Batta AK, Shefer S, Tint GS, Belchis D, Shneider B, Puffenberger E, Bull L, Knisely AS: **Abnormal hepatic sinusoidal bile acid transport in an amish kindred is not linked to FIC1 and is improved by ursodiol.** *Gastroenterology* 2000, **119**:188-195.
64. Carlton VEH, Harris BZ, Puffenberger EG, Batta AK, Knisely AS, Robinson DL, Strauss KA, Shneider BL, Lim WA, Salen G, Morton DH, Bull LN: **Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT.** *Nat Genet* 2003, **34**:91-96.
65. Phillips MJ, Azuma T, Meredith SL, Squire JA, Ackerley CA, Pluthero FG, Roberts EA, Superina RA, Levy GA, Marsden PA: **Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood.** *Lancet* 2003, **362**:1090-1091.
66. Shneider BL, Fox VL, Schwarz KB, Watson CL, Ananthanarayanan M, Thevananthar S, Christie DM, Hardikar W, Setchell KD, Mieli-Vergani G, Suchy FJ, Mowat AP: **Hepatic basolateral sodium-dependent-bile acid transporter expression in two unusual cases of hypercholanemia and in extrahepatic biliary atresia.** *Hepatology* 1997, **2**:1176-1183.
67. Zhu QS, Xing W, Qian B, von Dippe P, Shneider BL, Fox VL, Levy D: **Inhibition of human m-epoxide hydrolase gene expression in a case of hypercholanemia.** *Biochim Biophys Acta* 2003, **1638**:208-216.

68. Gissen P, Johnson CA, Morgan NV, Stapelbroek JM, Forshew T, Cooper WN, McKiernan PJ, Klomp LW, Morris AA, Wraith JE, McClean P, Lynch SA, Thompson RJ, Lo B, Quarrell OW, Di Rocco M, Trembath RC, Mandel H, Wali S, Karet FE, Knisely AS, Houwen RH, Kelly DA, Maher ER: **Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome.** *Nat Genet* 2004, **36**:400-404.
69. Hadj-Rabia S, Baala L, Vabres P, Hamel-Teillac D, Jacquemin E, Fabre M, Lyonnet S, De Prost Y, Munnich A, Hachouel M, Smahi A: **Clauudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease.** *Gastroenterology* 2004, **127**:1386-1390.
70. Chagnon P, Michaud J, Mitchell G, Mercier J, Marion JF, Drouin E, Rasquin-Weber A, Hudson TJ, Richter A: **A missense mutation (R565W) in cirhin (FLJ14728) in North American Indian childhood cirrhosis.** *Am J Hum Genet* 2002, **71**:1443-1449.
71. Bull LN, Roche E, Song EJ, Pedersen J, Knisely AS, Hagen CB van Der, Eiklid K, Aagenaes O, Freimer NB: **Mapping of the locus for cholestasis-lymphedema syndrome (Agenes syndrome) to a 6.6-cM interval on chromosome 15q.** *Am J Hum Genet* 2000, **67**:994-999.
72. Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, Sokal EM, Bernard O: **Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.** *Hepatology* 1997, **25**:519-523.
73. Modi BP, Suh MY, Jonas MM, Lillehei C, Kim HB: **Ileal exclusion for refractory symptomatic cholestasis in Alagille syndrome.** *J Pediatr Surg* 2007, **42**:800-805.
74. Bustorff-Silva J, Sbraggia Neto L, Olímpio H, de Alcantara RV, Matsu-shima E, De Tommaso AM, Brandão MA, Hessel G: **Partial internal biliary diversion through a cholecystojejunocolonic anastomosis – a novel surgical approach for patients with progressive familial intrahepatic cholestasis: a preliminary report.** *J Pediatr Surg* 2007, **42**:1337-1340.
75. Stapelbroek JM, van Erpecum KJ, Klomp LW, Venneman NG, Schwartz TP, van Berge Henegouwen GP, Devlin J, van Nieuwkerk CM, Knisely AS, Houwen RH: **Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis.** *Hepatology* 2006, **43**:51-53.
76. Soubrane O, Gauthier F, DeVictor D, Bernard O, Valayer J, Houssin D, Chapis Y: **Orthotopic liver transplantation for Byler disease.** *Transplantation* 1990, **50**:804-806.
77. De Vree JML, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RPJ: **Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis.** *Gastroenterology* 2000, **119**:1720-1730.
78. Boyer JL: **Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease.** *Gastroenterology* 2005, **129**:735-740.
79. Trauner M, Wagner M, Fickel P, Zollner G: **Molecular regulation of hepatobiliary transport systems. Clinical implications for understanding and treating cholestasis.** *J Clin Gastroenterol* 2005, **39**:S111-124.
80. Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, Bull LN, Pawlikowska L, Bilezikçi B, Özçay F, László A, Tiszlavicz L, Moore L, Raftos J, Arnell H, Fischler B, Németh A, Papadogiannakis N, Cielecka-Kuszyk J, Jankowska I, Pawłowska J, Melin-Aldana H, Emerick KM, Whittington PF, Mieli-Vergani G, Thompson RJ: **Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency.** *Hepatology* 2006, **44**:478-486.
81. Van Mil SWC, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuck V, Moore GE, Lammert F, Glantz AG, Mattson LA, Whittaker J, Parker MG, White R, Williamson C: **Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy.** *Gastroenterology* 2007, **133**:507-516.
82. Paulusma CC, Folmer DE, Ho-Mok KS, de Waart DR, Hilarius PM, Verhoeven AJ, Oude Elferink RP: **ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity.** *Hepatology* 2008, **47**:268-278.
83. Ortiz D, Arias IM: **MDR3 mutations: A glimpse into Pandora's box and the future of canalicular pathophysiology.** *Gastroenterology* 2001, **120**:1549-1552.
84. Cutillo L, Najimi M, Smets F, Janssen M, Reding R, de Ville de Goyet J, Sokal EM: **Safety of living-related liver transplantation for progressive familial intrahepatic cholestasis.** *Pediatr Transplant* 2006, **10**:570-574.
85. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, Lugt NM van der, Van Roon MA: **Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipids from bile and to liver.** *Cell* 1993, **75**:451-462.
86. Wang R, Lam P, Liu L, Forrest D, Youssef IM, Mignault Diane, Phillips MJ, Ling V: **Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein.** *Hepatology* 2003, **38**:1489-1499.
87. Pawlikowska L, Groen A, Eppens EF, Kunne C, Ottenhoff R, Looije N, Knisely AS, Killeen NP, Bull LN, Oude Elferink RPJ, Freimer NB: **A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion.** *Human Mol Gen* 2004, **13**:881-892.
88. Henderson CJ, Pass GJ, Roland Wolf C: **The hepatic cytochrome P450 reductase null mouse as tool to identify a successful candidate entity.** *Toxicology Letters* 2006, **162**:111-117.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

